Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Annalisa Guida1, Laurence Albiges2

  • 1University of Modena and Reggio Emilia, Modena, Italy.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary

Bone metastases are common in renal cell carcinoma, causing severe complications and impacting quality of life. This review covers systemic treatments, bone-targeting agents, and local therapies for managing bone metastases in mRCC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Cancer cell·2026
Same author

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

European urology focus·2026
Same author

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.

European urology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

British journal of cancer·2026

Area of Science:

  • Oncology
  • Bone Metastasis Research

Background:

  • Bone metastases (BMs) are a frequent complication in cancer patients, significantly increasing morbidity.
  • Metastatic renal cell carcinoma (mRCC) frequently involves bone, leading to severe complications like fractures, spinal cord compression, and pain.
  • Hypercalcemia in mRCC is a common feature and a recognized indicator of poor prognosis.

Purpose of the Study:

  • To review current evidence on managing bone metastases in renal cell carcinoma.
  • To discuss the role of systemic treatments, bone-targeting agents, and local therapies in the context of mRCC bone metastases.
  • To emphasize the importance of evaluating systemic disease prognosis and treatment goals for optimal patient care.

Main Methods:

  • Literature review of current evidence on bone metastases management in mRCC.
Keywords:
Agents ciblant l’osBone metastasesBone targettingCancer du reinLocal treatmentMétastases osseusesSystemic therapyTraitement localTraitementsagentsmRCCmétastatiquesystémiques

Related Experiment Videos

  • Analysis of systemic treatments, bone-targeting agents, and local therapeutic approaches.
  • Discussion on prognostic factors and treatment goal setting.

    • Main Results:

    • Bone metastases significantly impact prognosis and quality of life in mRCC patients.
    • Multimodal evaluation is crucial for optimizing the care and quality of life for patients with mRCC and BMs.
    • Systemic treatments, bone-targeting agents, and local therapies play key roles in managing BMs.

    Conclusions:

    • Effective management of bone metastases in mRCC requires a comprehensive, multimodal approach.
    • Understanding the prognosis of systemic disease and defining treatment goals are essential for selecting appropriate strategies.
    • Optimizing care for mRCC patients with bone metastases improves outcomes and quality of life.